Japanese encephalitis is the main cause of viral encephalitis in Asia. In a previous single-arm vaccine trial, an inactivated chromatographically purified Japanese encephalitis Vero cell vaccine (CVI-JE; JEVACTM) was safe and immunogenic in 152 Thai children aged 1–3 years receiving a 2-dose primary immunization and booster dose 1 year later. We conducted a 5-year follow-up assessment of the persistence of the immune response the 144 children remaining in this cohort after first booster dose. Immunity was assessed by 50% plaque reduction neutralization test annually for up to 5 years post-booster. Seroprotection rates (95%CI) decreased from 100% (97.1–100) at 1 year post-booster to 93% (85.0–98.3) at 5 years post-booster. No serious vaccine...
Background: Genotype I (GI) Japanese encephalitis virus (JEV) that replaced GIII virus has become th...
Background: Young travelers to South-East Asia may be at risk for Japanese encephalitis (JE). Method...
BACKGROUND: In July, 1999, a single dose of live-attenuated SA 14-14-2 Japanese encephalitis vaccine...
BACKGROUND: This study evaluated the effect of a booster vaccination of a new, live attenuated, Japa...
BackgroundThe burden of Japanese encephalitis (JE) is substantial and is arguably one of the most se...
Out of 98 subjects who had participated in the 2000 JE vaccination campaign, 69 people were enrolled...
Attenuated SA14-14-2 Japanese encephalitis (JE) vaccine has been administered safely and effectively...
AbstractBackgroundThe inactivated Vero cell-derived vaccine (JE-VC, IXIARO) has replaced the traditi...
AbstractBackgroundJapanese encephalitis is a mosquito-borne viral disease endemic in most countries ...
AbstractBackgroundThe performance of live attenuated Japanese Encephalitis SA 14-14-2 vaccine (CD-JE...
Background: Japanese encephalitis (JE) is the most important cause of viral encephalitis in Asia. ;M...
A new live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) has been developed based ...
Background. Japanese encephalitis (JE) is a vaccine-preventable acute disease. We report the results...
A mass Japanese encephalitis (JE) vaccination program targeting children was launched in Taiwan in 1...
The authors aimed to evaluate the safety and immunogenicity of a live attenuated SA14-14-2 Japanese ...
Background: Genotype I (GI) Japanese encephalitis virus (JEV) that replaced GIII virus has become th...
Background: Young travelers to South-East Asia may be at risk for Japanese encephalitis (JE). Method...
BACKGROUND: In July, 1999, a single dose of live-attenuated SA 14-14-2 Japanese encephalitis vaccine...
BACKGROUND: This study evaluated the effect of a booster vaccination of a new, live attenuated, Japa...
BackgroundThe burden of Japanese encephalitis (JE) is substantial and is arguably one of the most se...
Out of 98 subjects who had participated in the 2000 JE vaccination campaign, 69 people were enrolled...
Attenuated SA14-14-2 Japanese encephalitis (JE) vaccine has been administered safely and effectively...
AbstractBackgroundThe inactivated Vero cell-derived vaccine (JE-VC, IXIARO) has replaced the traditi...
AbstractBackgroundJapanese encephalitis is a mosquito-borne viral disease endemic in most countries ...
AbstractBackgroundThe performance of live attenuated Japanese Encephalitis SA 14-14-2 vaccine (CD-JE...
Background: Japanese encephalitis (JE) is the most important cause of viral encephalitis in Asia. ;M...
A new live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) has been developed based ...
Background. Japanese encephalitis (JE) is a vaccine-preventable acute disease. We report the results...
A mass Japanese encephalitis (JE) vaccination program targeting children was launched in Taiwan in 1...
The authors aimed to evaluate the safety and immunogenicity of a live attenuated SA14-14-2 Japanese ...
Background: Genotype I (GI) Japanese encephalitis virus (JEV) that replaced GIII virus has become th...
Background: Young travelers to South-East Asia may be at risk for Japanese encephalitis (JE). Method...
BACKGROUND: In July, 1999, a single dose of live-attenuated SA 14-14-2 Japanese encephalitis vaccine...